Overview

Anlotinib in Treatment of Recurrent Small Cell Lung Cancer

Status:
Unknown status
Trial end date:
2020-05-01
Target enrollment:
Participant gender:
Summary
Exploring the efficacy and safety of Anlotinib in patients with relapsed small cell lung cancer
Phase:
Phase 2
Details
Lead Sponsor:
Beijing Cancer Hospital